[HTML][HTML] Pancreatic cancer from bench to bedside: molecular pathways and treatment options
C Kosmidis, K Sapalidis, E Kotidis… - Annals of …, 2016 - ncbi.nlm.nih.gov
In the last forty years the pancreatic cancer treatment has made advances, however; still
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
[引用][C] Pancreatic cancer from bench to bedside: molecular pathways and treatment options
C Kosmidis, K Sapalidis, E Kotidis… - Annals of Translational …, 2016 - cir.nii.ac.jp
Pancreatic cancer from bench to bedside: molecular pathways and treatment options | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
[HTML][HTML] Pancreatic cancer from bench to bedside: molecular pathways and treatment options
C Kosmidis, K Sapalidis, E Kotidis… - Annals of …, 2016 - atm.amegroups.org
In the last forty years the pancreatic cancer treatment has made advances, however; still
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
[PDF][PDF] Pancreatic cancer from bench to bedside: molecular pathways and treatment options
C Kosmidis, K Sapalidis, E Kotidis, N Mixalopoulos… - 2016 - cdn.amegroups.cn
In the last forty years the pancreatic cancer treatment has made advances, however; still
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
Pancreatic cancer from bench to bedside: molecular pathways and treatment options
C Kosmidis, K Sapalidis, E Kotidis… - Annals of …, 2016 - pubmed.ncbi.nlm.nih.gov
In the last forty years the pancreatic cancer treatment has made advances, however; still
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
[PDF][PDF] Pancreatic cancer from bench to bedside: molecular pathways and treatment options
C Kosmidis, K Sapalidis, E Kotidis, N Mixalopoulos… - 2016 - researchgate.net
In the last forty years the pancreatic cancer treatment has made advances, however; still
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
Pancreatic cancer from bench to bedside: molecular pathways and treatment options.
C Kosmidis, K Sapalidis, E Kotidis… - Annals of …, 2016 - europepmc.org
In the last forty years the pancreatic cancer treatment has made advances, however; still
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
Pancreatic cancer from bench to bedside: molecular pathways and treatment options
C Kosmidis, K Sapalidis, E Kotidis… - Annals of …, 2016 - atm.amegroups.org
In the last forty years the pancreatic cancer treatment has made advances, however; still
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …
novel drugs are needed. It is known that the five year survival rate remains around 5%. The …